$EOLS News

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

Evolus: The Injectable Platform Is Becoming The Real Moat

Evolus, Inc. 2026 Q2 - Results - Earnings Call Presentation

Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ...

Evolus Q2 Earnings Call Highlights

Evolus (NASDAQ:EOLS) Tops Q2 EPS Estimates and Raises Revenue Guidance, Shares Gain 5.7%

Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Evolus Q2 EPS $(0.12), Sales $84.084M Beat $81.603M Estimate

Evolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M Est

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Evolus to Report Second Quarter Financial Results on August 5, 2026

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Evolus Enters Into Exclusive Licensing And Distribution Agreement With IBSA To Develop And Commercialize Profhilo In US

BTIG Reiterates Buy on Evolus, Maintains $13 Price Target

Evolus Files Prospectus To Offer Up To $250M Of Securities

Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus, Inc. 2026 Q1 - Results - Earnings Call Presentation